Results 91 to 100 of about 54,330 (287)
Haematologica, 2010 Background The aim of this study was to validate the Mantle Cell Lymphoma International Prognostic Index in a population-based cohort and to study the relevance of its revisions.Design and Methods We analyzed data from 178 unselected patients with stage ...
Saskia A.M. van de Schans +4 more
doaj +1 more source
Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling [PDF]
, 1983 BACKGROUND: Mantle cell lymphoma (MCL) is currently an incurable entity, and new therapeutic approaches are needed. We have applied a high-throughput phospho-proteomic technique to MCL cell lines to identify activated pathways and we have then validated ...
Chiara Pighi +12 more
core +1 more source
American Journal of Hematology, Volume 101, Issue 6, Page 1388-1397, June 2026.ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth.
Arushi Khurana +14 more
wiley +1 more source
HOXD8 exerts a tumor-suppressing role in colorectal cancer as an apoptotic inducer [PDF]
, 2017 Homeobox (HOX) genes are conserved transcription factors which determine the anterior-posterior body axis patterning. HOXD8 is a member of HOX genes deregulated in several tumors such as lung carcinoma, neuroblastoma, glioma and colorectal cancer (CRC ...
Mansour, Mohammed A., Senga, Takeshi
core +1 more source
Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs
Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri +10 more
wiley +1 more source
Diagnostic Cytopathology, Volume 54, Issue 6, Page 449-460, June 2026.ABSTRACT Background Fine‐needle aspiration biopsy (FNAB) is the preferred first‐line diagnostic tool for evaluating lymphadenopathy due to its minimally invasive nature and cost‐effectiveness. However, cytopathological interpretation of lymph node FNAB remains challenging because of the wide morphological spectrum of lymphoid lesions.
Immacolata Cozzolino +5 more
wiley +1 more source
Haematologica, 2018 Mantle cell lymphoma patients have variable clinical courses, ranging from indolent cases that do not require immediate treatment to aggressive, rapidly progressing diseases.
Riccardo Bomben +20 more
doaj +1 more source
CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies [PDF]
, 2016 Expression of CD20 antigen by the most of transformed B cells is believed to be the driving force for targeting this molecule by using anti-CD20 monoclonal antibodies. While it is true that most lymphoma/leukemia patients can be cured, these regimens are
Ahmadzadeh, V. +2 more
core +1 more source
Treatment Outcomes and Overall Survival of Patients With B‐Cell Prolymphocytic Leukemia
eJHaem, Volume 7, Issue 3, June 2026.ABSTRACT Introduction B‐cell prolymphocytic leukemia (B‐PLL) is a rare, aggressive leukemic B‐cell malignancy historically associated with poor outcomes and recently reclassified in the WHO Fifth Edition but retained as a distinct entity in the ICC.
Daniel A. Ermann +6 more
wiley +1 more source